Home
HomeThe Erasmus MC Biomedical Fund is an independent venture capital fund focusing on early stage companies and (university) spin-outs in the biotechnology and biomedical field with a presence in the Rotterdam region.The fund targets companies that are developing commercially promising products and technologies in life sciences, including: pharmaceuticals, biotechnology, information technology and other high technology opportunities that offer venture capital returns. |
Latest news07-09-2011
arGEN-X presents significant progress at Biopharm America 2011
More...06-09-2011
Skyline Diagnostics and Clavis Pharama to collaborate
More...23-02-2011
Arcarios scientists publishes latest findings in rheumatology.
More...25-08-2010
Arcarios B.V. announces closing of financing round
More...08-07-2010
arGEN-X granded broad patent covering its antibody™ platform
More...01-03-2010
arGEN-X SIMPLE AntIBODY™ PlATFORM SET TO TRANSFORM
More...01-02-2010
arGEN-X featured in In Vivo – Start UP
More...05-01-2010
Skyline Diagnostics raises EUR 5 million in Series B financing
More... |
|
